Early-phase and translational research on retatrutide, a GLP-1/GIP/glucagon tri-agonist in development for obesity and metabolic disease.
Also known as: Retatrutide, LY3437943, triple incretin agonist
No claims extracted for this topic
Retatrutide (also known as Retatrutide, LY3437943, triple incretin agonist). Early-phase and translational research on retatrutide, a GLP-1/GIP/glucagon tri-agonist in development for obesity and metabolic disease.
As of 2026-06-10, the scientific consensus on Retatrutide is unknown. No claims extracted for this topic
This evidence brief synthesizes Synapse's enriched cardiology corpus; cite as synapsesocial.com/topics/6a20b94c2eacf7592fbe2c12.
Deterministic synthesis from Synapse's enriched corpus — 52 words. No AI-generated novel content; every figure is sourced from the underlying paper, guideline, or trial record linked on this page.
Explore all Retatrutide research on Synapse with AI-enriched clinical evidence, PICO analysis, and methodology classification.
Search Retatrutide PapersPowered by Synapse — AI-enriched analysis of 600,000+ peer-reviewed papers